Physician
Jafferi, Ali
Jafferi, Ali was paid $9K by Medicaid between Jan 2018 and Dec 2024, across 64 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 91% of everything it billed.
33Billing provider infoJAFFERI, ALI
LANCASTER, CA 93536
LANCASTER, CA 93536
33aNPI1912042235assigned 02/21/2007
33bProvider typeInternal Medicine Physician
28Total paid$9K
24GClaims42,521
24DCodes billed64
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in California
Rank by total paid#1,425 of 2,679
Median peer was paid$13K
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,609 | $5K | |
| 2019 | 3,169 | $4K | |
| 2020 | 4,893 | $0.00 | |
| 2021 | 6,280 | $0.00 | |
| 2022 | 7,311 | $0.00 | |
| 2023 | 7,930 | $0.00 | |
| 2024incomplete | 10,329 | $0.00 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 91% | 3,706 | 3,376 | $9K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.4% | 2,122 | 1,930 | $505.89 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.8% | 2,981 | 2,498 | $169.08 |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.3% | 204 | 172 | $120.23 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 847 | 813 | $42.78 |
| 86703 | 0% | 332 | 331 | $0.00 | |
| 99442 | 0% | 2,113 | 1,853 | $0.00 | |
| 80061 | Lipid panel | 0% | 2,988 | 2,967 | $0.00 |
| 82540 | 0% | 514 | 508 | $0.00 | |
| 3078F | 0% | 724 | 655 | $0.00 | |
| 83540 | 0% | 151 | 146 | $0.00 | |
| 3077F | 0% | 205 | 195 | $0.00 |
52 more codes
| 82274 | 0% | 323 | $0.00 | |
| 99204 | Doctor's office visit, new patient (more involved) | 0% | 25 | $0.00 |
| 91300 | 0% | 33 | $0.00 | |
| 80076 | 0% | 94 | $0.00 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 0% | 15 | $0.00 |
| 85610 | 0% | 14 | $0.00 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 0% | 60 | $0.00 |
| 84439 | 0% | 42 | $0.00 | |
| 81003 | 0% | 30 | $0.00 | |
| 1033F | 0% | 37 | $0.00 | |
| 3051F | 0% | 12 | $0.00 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 0% | 44 | $0.00 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 29 | $0.00 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 0% | 2,438 | $0.00 |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 3,461 | $0.00 |
| 85027 | 0% | 671 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 6,492 | $0.00 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 786 | $0.00 |
| 80053 | Comprehensive metabolic panel | 0% | 3,626 | $0.00 |
| 3074F | 0% | 699 | $0.00 | |
| 1111F | 0% | 316 | $0.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 592 | $0.00 |
| 99443 | 0% | 85 | $0.00 | |
| 80048 | Basic metabolic panel (calcium, ionized) | 0% | 668 | $0.00 |
| 1220F | 0% | 1,116 | $0.00 | |
| 4450F | 0% | 193 | $0.00 | |
| 87522 | Neg quan hep c or qual rna | 0% | 64 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 440 | $0.00 |
| 82043 | 0% | 514 | $0.00 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 0% | 93 | $0.00 |
| 90656 | 0% | 41 | $0.00 | |
| 3079F | 0% | 258 | $0.00 | |
| 82607 | 0% | 25 | $0.00 | |
| 3044F | 0% | 344 | $0.00 | |
| 82728 | 0% | 142 | $0.00 | |
| 99441 | 0% | 582 | $0.00 | |
| 3080F | 0% | 109 | $0.00 | |
| 86780 | 0% | 118 | $0.00 | |
| 1000F | 0% | 101 | $0.00 | |
| 3075F | 0% | 218 | $0.00 | |
| 81001 | 0% | 270 | $0.00 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 0% | 99 | $0.00 |
| 85008 | 0% | 30 | $0.00 | |
| 83550 | 0% | 70 | $0.00 | |
| 83735 | 0% | 46 | $0.00 | |
| 2001F | 0% | 15 | $0.00 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 29 | $0.00 |
| 85652 | 0% | 12 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 42 | $0.00 |
| 90686 | 0% | 18 | $0.00 | |
| 86592 | 0% | 41 | $0.00 | |
| 92250 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.